Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)-Reference-Cited by-同舟云学术

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)

Published:2023-08 Issue: Volume:182 Page:107261
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Katakami Nobuyuki,Nishimura Takashi,Hidaka Yu,Hata Akito,Nishino Kazumi,Mori Masahide,Hirashima Tomonori,Takase Naoto,Kaneda Toshihiko,Ohnishi Hisashi,Morita Satoshi,Hatachi Yukimasa

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV Lung cancer—CSP-HOR 13;Katakami;J. Thorac. Oncol.,2014

2. Reducing the burden of bone metastases: current concepts and treatment options;von Moos;Support Care Cancer,2013

3. Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents;Poon;Clin. Oncol. (R. Coll. Radiol.),2013

4. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—The zoledronic acid lung cancer and other solid tumors study group;Rosen;J. Clin. Oncol.,2003

5. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study;Stopeck;J. Clin. Oncol.,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis;Biomedicines;2024-05-13

2. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers;Frontiers in Endocrinology;2024-01-08